Shionogi Business Partner Co., Ltd.
Basic information
- Head office
- Shionogi Michishiocho Building, 4-7-6 Michishiocho, Chuo-ku, Osaka, 541-0045
- Chief executive
- Yuuji Hosokawa
- Capital
- 10,000,000 JPY
- Employees (non-consolidated)
- Employees (consolidated)
- 274 people
- Start date
- 2017-04-03
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Burn foundation of America | ||||||||
| Gloridge | ||||||||
| V:DRIVE | ||||||||
| Verizon社 | ||||||||
| Accenture Corporation | ||||||||
| キープ・ママ・スマイリング | ||||||||
| シオノギキャリア開発センター株式会社 | ||||||||
| モリス郡異宗教間フードパントリー ネットワーク | ||||||||
| 全国食支援活動協力会 | ||||||||
| 秋田市医師会 | ||||||||
| 秋田県医師会 | ||||||||
|
|
||||||||
| Asahi Group Japan subsidiary, Asahi Beverage Co., Ltd. | ||||||||
|
|
||||||||
|
|
||||||||
|
|
Network
History
Shionogi Saburo founded the Shionogi Saburo Store in Michishiocho, Osaka, selling traditional Japanese and Western medicines.![]()
On March 17, 1878, on his 24th birthday, he established the pharmaceutical wholesaler 'Shionogi Saburo Shoten' at 3-12 Dousho-cho, Osaka.![]()
Eight years after founding, in 1886, when Western medicine began to spread widely, the company started importing and selling Western drugs.![]()
Manufactured and sold the first in-house antacid 'Antacidin', trademark registered with the 'Bento' mark.![]()
In 1909, following the graduation of Shionogi Saburo's second son, Nagajiro, from the Pharmaceutical Department of Tokyo Imperial University, SHIONOGI began serious pharmaceutical research. Nagajiro started trial production of the antacid, successfully commercialized it. This stomach-protecting antacid 'Antachijin' became the first self-developed new drug at Shionogi Saburo Shoten.![]()
In 1909, the balance mark was registered as a trademark. SHIONOGI's symbol is derived from the 'balance weights' used when measuring medicine on a scale.![]()
In 1910, a new pharmaceutical factory 'Shionogi Pharmaceutical Factory' was built in Nishinari-gun, Osaka Prefecture (now Fukushima-ku, Osaka City), and began full operation in 1910.![]()
Merged Shionogi Saburo Store and Shionogi Pharmaceutical Plant, reorganized into Shionogi Shoten Co., Ltd.![]()
Established Kuse Factory in Amagasaki, Hyogo Prefecture (now Kuse Office), and set up a laboratory within the factory.![]()
In 1945, rapid hyperinflation after the war, escalating price increases caused chaos, frozen corporate deposits, and termination of wartime compensation, leading SHIONOGI to become nearly bankrupt and fall into the worst management condition since its founding.![]()
Constructed Central Research Institute in Fukushima-ku, Osaka (now consolidated into the Pharmaceutical Research Center).![]()
Established Animal Pharmaceutical Division (transferred in 2002), Plant Pharmaceutical Division (transferred in 2001), commenced clinical laboratory operations (transferred in 2002): Established Taiwan Shionogi Pharmaceutical (Ltd.).![]()
Constructed Shionogi Shibuya Building (Shibuya-ku, Tokyo) and New Drug Research Institute (Toyonaka City, Osaka Prefecture) (now Medical Research Center)![]()
Constructed Medical Science Research Institute within Settsu plant site (now consolidated into Medical Research Center) and launched oxacyl antibiotic 'Fullmarin'![]()
Established Shionogi Comprehensive Services Co., Ltd. (now Shionogi Business Partner Co., Ltd.) and acquired capsule business from Eli Lilly (sold in 2005)![]()
Adopted Shionogi Code of Conduct (revised 2012), established Oomori Pharmaceutical Co., Ltd. (sold 2002), and established Bushu Pharmaceutical Co., Ltd. (sold 2010)![]()
From April 2000 to March 2005, to consolidate the pharmaceutical business, we transferred the sales of botanical medicines, veterinary medicines, and pharmaceutical wholesale to other companies.![]()
Established Shionogi USA, Inc. (now Shionogi Inc.) and international JV Shionogi-GlaxoSmithKline Pharmaceuticals LLC (later Shionogi-ViiV Healthcare LLC) to begin joint research and development of HIV treatment drugs![]()
Start of Second Medium-Term Management Plan, launch of cholesterol-lowering drug 'Crestor', and launch of carbapenem antibiotic 'Finibax'![]()
From April 2005 to March 2010, in pursuit of narrowing research areas and accelerating development, we established a development subsidiary in the United States in 2001, and also began joint development of new drugs with GlaxoSmithKline in the United Kingdom.![]()
Acquired U.S. Sciele Pharma, Inc. (now Shionogi Inc.) and established Shionogi Drug Discovery Innovation Center in collaboration with Hokkaido University; launched hypertension drug 'Ilbetan', acne treatment drug 'Deferin', and idiopathic pulmonary fibrosis drug 'Pirespa'![]()
Start of Third Medium-Term Management Plan, established Shionogi Techno Advance Research Co., Ltd., opened Osaka University Graduate School of Medicine PET Molecular Imaging Center, launched influenza antiviral drug 'Rapiacta', and launched antidepressant 'Sainbarta'![]()
From April 2010 to March 2014, we acquired the Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Limited in 2011, and established the development subsidiary Shionogi Limited in the United Kingdom in 2012, thereby advancing our basic policy of globalization.![]()
Acquired Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Ltd. and constructed new SPRC4 building within Medical Research Center (SPRC) to consolidate drug discovery research functions![]()
Established European subsidiary Shionogi Limited (UK), signed new framework agreement with Vibe Healthcare regarding HIV treatment drugs, launched cancer pain injection 'OkiFast', and launched hypertension drug 'Aimix'![]()
Established Beijing Shionogi Pharmaceutical Technology Co., Ltd. (China) and Shionogi Singapore Pte. Ltd.; changed royalty agreement on Crestor with AstraZeneca; launched postmenopausal vaginal atrophy drug 'Osphena' in the U.S.; launched hypertension drug 'Iltra'![]()
Start of Medium-Term Management Plan 'Shionogi Growth Strategy 2020 (SGS2020)', launched HIV treatment drug 'Tebikei'![]()
In April 2014, the new medium-term management plan set the vision of 'growing as a drug discovery-oriented pharmaceutical company', defined ROE (return on equity) as one of the management indicators, clarified the items to be accomplished over the next three years, and clearly indicated that we would work toward the 2020 management goal by reviewing results and challenges annually on a rolling basis.![]()
Launch of the HIV treatment drug 'Trimek' : Launch of the allergen immunotherapy drug 'Asithea' : Launch of the thrombocytopenia treatment drug 'Mulpleta'![]()
Update of the mid-term management plan 'SGS2020' : Establishment of Shionogi Healthcare Co., Ltd. : Launch of the high cholesterol treatment drug 'Crestol OD tablets'![]()
Establishment of domestic group companies: Shionogi Career Development Center Inc., Shionogi Digital Science Inc., Shionogi Business Partner Inc., Shionogi Pharma Pharmacovigilance Center Inc., Shionogi Marketing Solutions Inc. : Launch of the cancer pain treatment drug 'Mesapain' : Launch of the ADHD treatment drug 'Intunib' : Launch of the opioid-induced constipation treatment drug 'Symproic' in the United States : Launch of the opioid-induced constipation treatment drug 'Soinproik' : Launch of the sustained cancer pain treatment drug 'Oxycontin TR tablets'![]()
Establishment of Shionogi Pharma Inc. : Establishment of European subsidiary Shionogi B.V. : Launch of the anti-influenza virus drug 'Zoflura' : Launch of the thrombocytopenia treatment drug 'Mulpleta' in the United States : Launch of the anti-HIV drug 'Jaruka'![]()
Establishment of the joint venture company 'Stream-I Co., Ltd.' with M3 Inc. : Consolidation of UMN Pharma Inc. as a subsidiary : Opening of the Shionogi Education and Training Center in Amagasaki City : Launch of the opioid-induced constipation treatment drug 'Rizmoic' in Europe : Launch of the anti-influenza virus drug 'Shufukou' in Taiwan : Launch of the ADHD treatment drug 'Vivance'![]()
Launch of the mid-term management plan 'Shionogi Transformation Strategy 2030 (STS2030)' : Establishment of the joint venture company 'Ping An Shionogi Co., Ltd.' with China Ping An Insurance : Full acquisition of Tetra Inc. in the United States : Acquisition of Nagase Pharmaceutical as a subsidiary by Shionogi Pharma : Launch of the gram-negative bacterial infection treatment drug 'Fetroja' in the United States : Launch of the gram-negative bacterial infection treatment drug 'Fetcroja' in Europe![]()
Launch of the sewage ecology survey service for COVID-19 : Launch of the opioid-induced constipation treatment drug 'Soinproik' in Taiwan![]()
News
There is no news.
Public records
National Tax Agency basic information8120001204745
- Trade name
- シオノギビジネスパートナー株式会社
- Trade name (kana)
- シオノギビジネスパートナー
- Name in English
- Corporation type
- 301
- Address
- 〒541-0045 大阪府大阪市中央区道修町4丁目7番6号
- Postal code
- 5410045
- Prefecture code
- 27
- City code
- 128
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2017-04-12
- Update date
- 2023-07-07
- Change date
- 2023-07-03
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- 令和5年7月1日大阪市中央区道修町四丁目7番6号シオノギファーマコビジランスセンター株式会社(6120001204747)を合併
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 71
- Correction type
- 0
- Trade name image ID
- Address image ID
- Sequence number
- 4370246
METI gBizINFO8120001204745
- Corporate number
- 8120001204745
- Trade name
- シオノギビジネスパートナー株式会社
- Trade name (kana)
- シオノギビジネスパートナー
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 大阪府大阪市中央区道修町4丁目7番6号
- Postal code
- 5410045
- Prefecture
- 大阪府
- Prefecture code
- 27
- City or district
- 大阪市中央区
- City code
- 128
- Street address
- 道修町4丁目7番6号
- Organisation type
- 301
- Processing type
- 71
- Correction type
- 0
- Status
- Representative
- Capital
- Employees
- 268
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- R:サービス業(他に分類されないもの)
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2023-07-07
- Key information
- 8120001204745